Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses

Jose M. Serra López-Matencio, Yaiza Pérez García, Virginia Meca-Lallana, Raquel Juárez-Sánchez, Angeles Ursa, Lorena Vega-Piris, Dora Pascual-Salcedo, Annick de Vries, Theo Rispens, Cecilia Muñoz-Calleja

Open source

DOI: 10.3389/fneur.2021.716548
Published: 2021-10-07
Container: Frontiers in Neurology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fneur.2021.716548,
  title = {Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses},
  author = {Jose M. Serra López-Matencio and Yaiza Pérez García and Virginia Meca-Lallana and Raquel Juárez-Sánchez and Angeles Ursa and Lorena Vega-Piris and Dora Pascual-Salcedo and Annick de Vries and Theo Rispens and Cecilia Muñoz-Calleja},
  year = {2021},
  journal = {Frontiers in Neurology},
  doi = {10.3389/fneur.2021.716548},
  url = {https://doi.org/10.3389/fneur.2021.716548}
}

RIS

TY  - JOUR
TI  - Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
AU  - Jose M. Serra López-Matencio
AU  - Yaiza Pérez García
AU  - Virginia Meca-Lallana
AU  - Raquel Juárez-Sánchez
AU  - Angeles Ursa
AU  - Lorena Vega-Piris
AU  - Dora Pascual-Salcedo
AU  - Annick de Vries
AU  - Theo Rispens
AU  - Cecilia Muñoz-Calleja
PY  - 2021
JO  - Frontiers in Neurology
DO  - 10.3389/fneur.2021.716548
UR  - https://doi.org/10.3389/fneur.2021.716548
ER  -

APA

López-Matencio, J. M. S., García, Y. P., Meca-Lallana, V., Juárez-Sánchez, R., Ursa, A., Vega-Piris, L., Pascual-Salcedo, D., Vries, A. D., Rispens, T., & Muñoz-Calleja, C. (2021). Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses. Frontiers in Neurology. https://doi.org/10.3389/fneur.2021.716548

Source records

crossref · retrieved 2026-09-25T08:54:26.624Z